ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2547

Anti-Ribosomal P Antibody Has a Protective Role In The Development Of Chronic Kidney Disease In Patients With Lupus Nephritis

Kyung-Eun Lee1, Dong-Jin Park1, Tae-Jong Kim2, Yong-Wook Park1 and Shin-Seok Lee2, 1Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, 2Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus-Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications

Session Type: Abstract Submissions (ACR)

Background/Purpose: Anti-ribosomal P antibody (anti-P) in patients with systemic lupus erythematosus (SLE) is associated with neuropsychiatric manifestation. Of interest, recent studies have suggested that anti-P is a marker for renal flare and disease activity and is associated with renal histopathologic findings in patients with lupus nephritis (LN). However, the clinical relevance and prognostic value of anti-P in patients with LN are not well characterized. Therefore, we examined the association of the presence of anti-P with the identification of clinical, histopathologic, and prognostic values in Korean patients with biopsy-proven LN.

Methods: Seventy-nine patients with LN were included in this study based on the availability of kidney biopsy specimens. Sociodemographic, clinical, laboratory, and treatment-related data at the time of kidney biopsy and during follow-up were obtained by reviewing patients’ charts. Renal biopsy specimens were reclassified according to the ISN-RPS classification by two renal pathologists blinded to the previous classification. Anti-P was measured by immunoblot assay at the time of renal biopsy. Kaplan-Meier analysis was performed to estimate the probability of progression to chronic kidney disease (CKD) according to the presence of anti-P.

Results: Twenty-eight (35.4%) of 79 patients were positive for anti-P. Patients with anti-P had an earlier age at LN onset (26.6 ± 10.1 versus 34.7 ± 12.1, P = 0.005), higher SLEDAI 2000 score (12.7 ± 4.2 versus 10.5 ± 4.8, P = 0.029), and higher eGFR level (129.0 ± 47.6 versus 102.2 ± 41.5, P = 0.005) at the time of renal biopsy than those without. The autoantibody profiles in patients with anti-P were not different from those without; however, anti-Sm antibodies were more common in patients with anti-P (71.4% versus 37.3%, P = 0.004). The renal histopathologic findings showed that patients with anti-P had less interstitial inflammation (67.9% versus 94.1%, P = 0.003) in the activity index and less glomerular sclerosis (21.4% versus 45.1%, P = 0.037), less tubular atrophy (42.9% versus 66.7%, P = 0.040), and less interstitial fibrosis (57.1% versus 78.4%, P = 0.046) in the chronicity index. In addition, anti-P positivity was significantly associated with lower chronicity scores (1.29 ± 1.24 versus 2.25 ± 1.63, P = 0.006). Although 13 of 51 (25.5%) patients without anti-P progressed to CKD after a median follow-up of 47 (6–108) months, only 1 of 28 (3.6%) patients with anti-P developed CKD (P = 0.015).

Conclusion: Our findings have shown that although anti-P is associated with an earlier age of onset and higher disease activity at the time of LN diagnosis, anti-P has a protective role in the development of CKD in patients with LN.


Disclosure:

K. E. Lee,
None;

D. J. Park,
None;

T. J. Kim,
None;

Y. W. Park,
None;

S. S. Lee,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-ribosomal-p-antibody-has-a-protective-role-in-the-development-of-chronic-kidney-disease-in-patients-with-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology